Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020
Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
Changes in spirometry (FVC and FEV1 ) in a closed population of COPD patients using new standarized values for Mexican people Source: Eur Respir J 2003; 22: Suppl. 45, 69s Year: 2003
Differences in COPD: Smokers versus non smokers Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015
Does Smoking Cessation affect symptoms and FEV1 in smokers with mild COPD? Source: Virtual Congress 2020 – Smoking disease landscape: from inflammation to lung function and comorbidities Year: 2020
Comparison of breath VOCs collected from controls, healthy smokers, smokers with COPD, and ex-smokers with COPD at two sites Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015
Clinical consideration and lung function in different groups of COPD patients (smokers, ex-smokers, nonsmokers) Source: International Congress 2017 – Smoking and health hazards Year: 2017
COPD hospitalizations in never smokers: comparison with current smokers Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016
FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017
The effect of stop smoking on FEV1 and FEV1/FVC Source: Eur Respir J 2003; 22: Suppl. 45, 307s Year: 2003
Which markers other than FEV1 reflect disease progression in COPD? Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004
Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1 Source: Eur Respir J 2004; 23: 497-498 Year: 2004
Do COPD smokers differ from healthy smokers in their readiness to stop smoking? Source: Eur Respir J 2004; 24: Suppl. 48, 249s Year: 2004
Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2005; 26: Suppl. 49, 510s Year: 2005
Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
The prevalence of patients with normal post-bronchodilator spirometry that fulfil the criteria for GOLD mild COPD using ECCS predicted equations Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019
Does spirometry in subjects GOLD stage zero change after one year of follow-up? Source: Eur Respir J 2004; 24: Suppl. 48, 503s Year: 2004
1 year RV/TLC change as a predictor of long term decline of FEV1 Source: International Congress 2018 – Biomarkers of COPD Year: 2018
Osteoprotogerin plasma concentrations is correlate with forced expiratory volume at 1 second (FEV1) in patients with COPD Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013